JT's Zerenex filing set to up ante in competitive Japan binder market
This article was originally published in Scrip
Executive Summary
Japan Tobacco's (JT) approval filing in Japan for JTT-751 (ferric citrate; licensed from Keryx Biopharmaceuticals) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) signals rising competition in an increasingly crowded local market for oral phosphate binding agents.